Press Release

<< Back
 View printer-friendly version
Editas Medicine to Present at Upcoming February Investor Conferences

CAMBRIDGE, Mass., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will present a company overview at two upcoming investor conferences in February.  Details of the presentations are as follows:

19th Annual BIO CEO & Investor Conference
Date: Monday, February 13, 2017
Time: 3:00 p.m. ET
Location: New York City
RBC Capital Markets 2017 Global Healthcare Conference
Date: Wednesday, February 22, 2017
Time: 10:30 a.m. ET
Location: New York City

Live webcasts of the presentations will be available on the Investors & Media section of the Editas website at  Archived replays will be available for approximately 30 days following the respective presentations.

About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes.  The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.


Media Contact

Dan Budwick
Pure Communications, Inc.
(973) 271-6085


Editas Investor Contact

Mark Mullikin
Editas Medicine, Inc.
(617) 401-9083


Primary Logo

Editas Medicine